Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) EBT (2022 - 2025)

Zentalis Pharmaceuticals has reported EBT over the past 4 years, most recently at -$34.8 million for Q4 2025.

  • Quarterly results put EBT at -$34.8 million for Q4 2025, up 27.06% from a year ago — trailing twelve months through Dec 2025 was -$136.6 million (up 17.55% YoY), and the annual figure for FY2025 was -$136.6 million, up 17.55%.
  • EBT for Q4 2025 was -$34.8 million at Zentalis Pharmaceuticals, down from -$26.7 million in the prior quarter.
  • Over the last five years, EBT for ZNTL hit a ceiling of $10.2 million in Q1 2024 and a floor of -$99.5 million in Q2 2023.
  • Median EBT over the past 4 years was -$50.4 million (2022), compared with a mean of -$50.0 million.
  • Biggest five-year swings in EBT: surged 116.74% in 2024 and later plummeted 574.11% in 2025.
  • Zentalis Pharmaceuticals' EBT stood at -$48.5 million in 2022, then dropped by 25.87% to -$61.1 million in 2023, then increased by 21.94% to -$47.7 million in 2024, then rose by 27.06% to -$34.8 million in 2025.
  • The last three reported values for EBT were -$34.8 million (Q4 2025), -$26.7 million (Q3 2025), and -$26.9 million (Q2 2025) per Business Quant data.